Media Center

Recent News

08/08/18ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial ResultsPrinter Friendly Version
08/06/18ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett SyndromePrinter Friendly Version
07/30/18ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018Printer Friendly Version
07/19/18ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and SecretaryPrinter Friendly Version
06/29/18ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)Printer Friendly Version
2018 | 2017 | 2016 | Archive

Company Information

Annual Report


Scientific Publications

Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).